jnj-26489112

Small moleculeexperimental

Clinical trial activity

4 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2007 (NCT00579384)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Loading structure…

SMILES

NS(=O)(=O)NC[C@H]1COc2cc(Cl)ccc2O1
Mol. weight
278.72 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • jnj26489112
  • jnj-26489112
  • jnj-26489112
  • jnj-26489112
  • n-((6-chloro-2,3-dihydrobenzo(1,4)dioxin-2-yl)methyl)sulfamide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01114698Phase 2Mar 1, 2011Johnson and Johnson
NCT01147887Phase 1Jun 1, 2010Johnson and Johnson
NCT01949610Phase 1Jan 1, 2010Johnson and Johnson
NCT00579384Phase 2Oct 1, 2007Johnson and Johnson
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Johnson and JohnsonFor profit4422007
1 organizations
Page 1 / 1